NeuroSense Therapeutics Warrant
NRSNW
4 hedge funds and large institutions have $229K invested in NeuroSense Therapeutics Warrant in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
2% more capital invested
Capital invested by funds: $224K → $229K (+$5K)
0% more funds holding
Funds holding: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$21.9K |
| 2 |
CS
Clear Street
New York
|
+$5.08K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EAM
1
Empery Asset Management
New York
| $82K | – | – | – |
|
2
Hudson Bay Capital Management
Stamford,
Connecticut
| $81K | – | – | – |
|
|
WAM
3
Warberg Asset Management
Winnetka,
Illinois
| $39K | +$21.9K | +53,104 | +221% |
|
|
CS
4
Clear Street
New York
| $27K | +$5.08K | +12,320 | +31% |
|
NRSNW Hedge Fund Activity: Q2 2022 in Review
4 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q2 2022, worth a combined $229K — up 2.2% from $224K a quarter earlier.
Fund positioning in NRSNW was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Warberg Asset Management, adding an estimated $21.9K.
- 4 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $229K of NeuroSense Therapeutics Warrant stock for Q2 2022, up 2.2% quarter-over-quarter.
- 0 funds opened new NeuroSense Therapeutics Warrant positions in Q2 2022 and 0 closed out.
- The largest NeuroSense Therapeutics Warrant buyer in Q2 2022 was Warberg Asset Management, an estimated $21.9K added.
Based on aggregated 13F filings for Q2 2022.